Chinook Therapeutics, Inc. Common Stock
KDNY
KDNY was delisted on the 10th of August, 2023.
135 hedge funds and large institutions have $931M invested in Chinook Therapeutics, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 43 funds opening new positions, 56 increasing their positions, 25 reducing their positions, and 12 closing their positions.
23,432% more call options, than puts
Call options by funds: $13.9M | Put options by funds: $59K
258% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 12
124% more repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 25
29% more funds holding
Funds holding: 105 → 135 (+30)
29% more funds holding in top 10
Funds holding in top 10: 7 → 9 (+2)
28% more capital invested
Capital invested by funds: $727M → $931M (+$203M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OCA
Octagon Capital Advisors
New York
|
+$18.8M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$18.3M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$16.7M |
| 4 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
+$13.9M |
| 5 |
SB
Samsara BioCapital
Palo Alto,
California
|
+$8.95M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$17.1M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$16.4M |
| 3 |
VA
VR Adviser
New York
|
-$12.5M |
| 4 |
AC
Armistice Capital
New York
|
-$12.4M |
| 5 |
IBT
International Biotechnology Trust
London,
United Kingdom
|
-$5.25M |
KDNY Hedge Fund Activity: Q2 2022 in Review
135 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Chinook Therapeutics, Inc. Common Stock (KDNY) for Q2 2022, worth a combined $931M — up 28% from $727M a quarter earlier.
Buyers outnumbered sellers: 43 funds opened new KDNY positions and 12 closed out — a net gain of 31 holders — while 56 added to existing stakes and 25 trimmed.
The largest buyer was Octagon Capital Advisors, adding an estimated $18.8M. The largest seller was Great Point Partners, cutting an estimated $17.1M.
- 135 institutional investors held Chinook Therapeutics, Inc. Common Stock (KDNY) as of Q2 2022, up from 105 in Q1 2022.
- Funds reported $931M of Chinook Therapeutics, Inc. Common Stock stock for Q2 2022, up 28% quarter-over-quarter.
- 43 funds opened new Chinook Therapeutics, Inc. Common Stock positions in Q2 2022 and 12 closed out, a net change of +31 holders.
- The largest Chinook Therapeutics, Inc. Common Stock buyer in Q2 2022 was Octagon Capital Advisors, an estimated $18.8M added.
- The largest Chinook Therapeutics, Inc. Common Stock seller in Q2 2022 was Great Point Partners, an estimated $17.1M sold.
Based on aggregated 13F filings for Q2 2022.